QUEBEC CITY, Oct. 3, 2013 /CNW Telbec/ - At an announcement made earlier
today, at the BioContact Quebec Biopharmaceutical Partnership
Symposium, Merck Canada confirmed its commitment to the Quebec life
sciences research innovation sector by allocating a total of $16
million in grants to four of Quebec's university hospital centres:
Université de Montréal, Université de Sherbrooke, Université Laval and
The grant received by each institution will be used to support health
research with a translational component conducted in areas of unmet
"At Merck, we strive to identify and support areas that will have the
most effect on fulfilling the unmet needs of patients, who are at the
core of everything we do. In addition, we want to contribute to
strengthening the life sciences sector in Quebec through research
performed by teams of world class scientists. We believe that with
these grants, we have achieved both of these goals," said Dr. Thomas R.
Cannell, President and Managing Director, Merck Canada Inc.
"Today's announcement proves without a doubt that world-class businesses
such as Merck have confidence in Quebec expertise to advance life
sciences research. It also helps reinforce the collaborative efforts of
numerous researchers from Quebec universities. High-calibre scientific
research is central to Quebec's development," said Pierre Duchesne,
Minister of Higher Education, Research, Science and Technology.
Developing a strong infrastructure in Quebec
"As populations age and diseases become increasingly chronic and
complex, the health care challenges we face are significant.
Collaborations like these are fundamental in advancing the biomedical
research being conducted by our outstanding scientists, and in
translating their discoveries into better health care for Quebecers. We
are tremendously proud to be partnering with Merck Research
Laboratories to bring the benefits of our work to society more
swiftly," said Dr. David Eidelman, Vice-Principal (Health Affairs) and
Dean of the Faculty of Medicine at McGill University.
"Université Laval's Faculty of Medicine would like to thank Merck for
its significant donation, which will allow us to create a fund
dedicated to research in biomedical sciences and the transfer of
knowledge. In the context of establishing Alliance Québec for
innovative research in life and health sciences, this donation
constitutes a vital contribution to the development of health research
in Quebec's National Capital. The Faculty of Medicine intends to use
some of the funds to support the work of young researchers," affirmed
Rénald Bergeron, Dean of the Faculty of Medicine at Université Laval.
"We want to express our gratitude to Merck Canada for supporting the
Faculté de médecine et des sciences de la santé (FMSS) at the
Université de Sherbrooke through this important grant. We feel
privileged to be part of Merck's new collaborative approach to R&D and
proud to bring our contribution to improving the health and well-being
of individuals and populations," said Dr. Pierre Cossette, Dean of the
Faculté de médecine et des sciences de la santé at the Université de
"We join all our academic colleagues in acknowledging that the support
announced today will not only help our teams of scientists remain at
the forefront of research, but it will also serve as a model for future
partnerships that are essential to the development of new and much
needed medical discoveries," said Dr. Hélène Boisjoly, Dean of Medicine
at Université de Montréal.
This announcement marks the latest contribution by Merck towards its
commitment to inject $100 million over five years in biopharmaceutical
R&D in Quebec. Today's announcement brings the total contributions by
Merck to approximately $84 million.
Note: All amounts expressed in this press release are in Canadian
dollars unless otherwise noted.
Today's Merck is a global healthcare leader working to help the world be
well. Merck is known as MSD outside the United States and Canada.
Through our medicines, vaccines, biologic therapies, and consumer and
animal products, we work with customers and operate in more than 140
countries to deliver innovative health solutions. We also demonstrate
our commitment to increasing access to healthcare through far-reaching
policies, programs and partnerships. For more information about our
operations in Canada, visit www.merck.ca.
About Université de Montréal
University of Montreal's Faculty of Medicine has the largest number of
medical school admissions in North America, is the first in Canada for
the number of admissions in medicine, rehabilitation, speech-language
pathology and audiology and the only medical school in Canada with a
nutrition department. Through its extensive health network and the
major responsibilities it has been given by the government of Québec in
terms of health care, the Faculty of Medicine plays a leading social
About Université de Sherbrooke
The Faculté de médecine et des sciences de la santé (FMSS) at the
Université de Sherbrooke is rooted in and committed to the communities
where it continues to evolve. Its mission is to provide training,
conduct research, and disseminate knowledge while fostering critical
and creative thinking with the goal of improving the health and
well-being of individuals and populations. The FMSS is the first
Canadian and first French-language faculty of medicine to be recognized
by the World Health Organization as a Collaborating Centre for the
training of human resources. With its pedagogical innovations which
have earned it an enviable reputation, and its five centres and thirty
research teams, over the years it has become a major faculty on the
Québec and international stage. The FMSS offers 89 study programs in
medicine, nursing, rehabilitation and many research programs.
About Université Laval
With more than 70 academic programs, including 16 at the master's and
doctoral levels, Canada's first French-speaking faculty of medicine
provides training to more than 4,000 students in health sciences
annually. Our 280 research professors actively take part in the
development of fundamental, clinical and population health research,
generating more than $130 million in scholarships, contracts and
grants. With our 40 research chairs and four affiliated research
centres, research activities at the Faculty contribute towards the
transfer of knowledge and improved population health.
About McGill University
Founded in 1829, the McGill Faculty of Medicine was the first faculty
established at the University and the first medical faculty in Canada.
Today, it comprises the Schools of Medicine, Physical and Occupational
Therapy, and Communication Sciences and Disorders, and the Ingram
School of Nursing, offering excellence in post-secondary education and
research that is internationally renowned. It is home to an exceptional
community of health care professionals, scientists, students and
support personnel committed to improving the health of Quebecers and
all of society. Through the Réseau universitaire intégré de santé
McGill, the Faculty of Medicine, together with its network of
affiliated teaching hospitals and partners, is also responsible for
coordinating access to training, research and health care for close to
1.8 million Quebecers across 63 per cent of the province's landmass.
The news release and photograph are available at www.cnw.ca.
Forward Looking Statement
This news release includes "forward-looking statements" within the
meaning of the safe harbor provisions of the United States Private
Securities Litigation Reform Act of 1995. These statements are based
upon the current beliefs and expectations of Merck's management and are
subject to significant risks and uncertainties. If underlying
assumptions prove inaccurate or risks or uncertainties materialize,
actual results may differ materially from those set forth in the
Risks and uncertainties include but are not limited to, general industry
conditions and competition; general economic factors, including
interest rate and currency exchange rate fluctuations; the impact of
pharmaceutical industry regulation and health care legislation in the
United States and internationally; global trends toward health care
cost containment; technological advances, new products and patents
attained by competitors; challenges inherent in new product
development, including obtaining regulatory approval; Merck's ability
to accurately predict future market conditions; manufacturing
difficulties or delays; financial instability of international
economies and sovereign risk; dependence on the effectiveness of
Merck's patents and other protections for innovative products; and the
exposure to litigation, including patent litigation, and/or regulatory
Merck undertakes no obligation to publicly update any forward-looking
statement, whether as a result of new information, future events or
otherwise. Additional factors that could cause results to differ
materially from those described in the forward-looking statements can
be found in Merck's 2012 Annual Report on Form 10-K and the company's
other filings with the Securities and Exchange Commission (SEC)
available at the SEC's Internet site (ww.sec.gov).
From left to right: Mr. Philippe Gros, PhD, Vice-Dean, Life Sciences,
McGill University; Pr. Daniel Bourbonnais, Associate Dean-Research and
Scientific Innovation, Université de Montréal; Pr. Jean-Pierre
Perreault, PhD, Vice-Dean of Research and Graduate Studies, Faculté de
médecine et des sciences de la santé, Université de Sherbrooke; Mr.
Denis Brière, President, Université Laval; Mr. Pierre Duchesne,
Minister of Higher Education, Research, Science and Technology; Dr.
Thomas R. Cannell, President and Managing Director, Merck Canada Inc.
Image with caption: "From left to right: Mr. Philippe Gros, PhD; Pr. Daniel Bourbonnais; Pr. Jean-Pierre Perreault, PhD; Mr. Denis Brière; Mr. Pierre Duchesne; Dr. Thomas R. Cannell (CNW Group/Merck)". Image available at: http://photos.newswire.ca/images/download/20131003_C6959_PHOTO_EN_31680.jpg
For further information:
NATIONAL Public Relations